Roche tosses out tau prospect, returning rights to UCB 4 years after placing $120M bet

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.